Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft

Vascular-targeting agents (VTAs) can be divided into two groups: anti-angiogenesis agents and vascular disrupting agents (VDAs). The purpose of this study was to evaluate the antineoplastic activity of a combination of the anti-angiogenesis agent, Endostar, and the VDA combretastatin, A4 phosphate (CA4P). This study is the first to evaluate the activity of this combination against tumors and the first to investigate the activity of the combination against osteosarcoma. Endostar combined with CA4P had a good anti-tumor effect with no significant toxicity, and was at least not inferior to adriamycin, which is the main drug for osteosarcoma. The use of VDAs combined with anti-angiogenic drugs can result in significantly enhanced anti-tumor effects, providing a novel approach to cancer treatment, which could effectively complement standard treatments. It is believed that this exciting new treatment has the potential to transform the management of cancer.

► This study evaluated the combination of vascular targeting (Endostar) and disrupting agents (CA4P) in osteosarcoma.
► This combination had a good anti-tumor activity with little toxicity.
► Their outcomes were comparable to adriamycin, the current gold standard of chemotherapy.
► This combination has synergy in the antitumor effect.